ARCHIVES

NKTR-102 Shows 29 Percent Response in Phase II Study

This article is from The Cancer Letter archive.

Vol. 34 No. 9 | September 30, 2011

Download PDF Visit The Full Archive

Related Articles

FDA Approves Rituxan For CLL

February 19, 2010

Blood Test Could Predict Relapse, Survival For Children, Young Adults With Leukemia

May 25, 2007

In Brief: La Jolla Foundation Receives Donated Buildings; Sinks Named Medical Director, Middlesex Hospital

April 27, 1990

FASEB Urges Congress To Fund Stem Cell Research.

July 27, 2001

In Brief: Fredrickson Okays NCI Reorganization, Plan At Hew; Miller Leave International Affairs Job

February 8, 1980

Femara Better Suppressor Of Estrogen, Study Finds

February 22, 2002